These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

665 related articles for article (PubMed ID: 33550776)

  • 1. Review of COVID-19 Vaccines and Their Evidence in Older Adults.
    Teo SP
    Ann Geriatr Med Res; 2021 Mar; 25(1):4-9. PubMed ID: 33550776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccines and Vaccination against SARS-CoV-2: Considerations for the Older Population.
    Weinberger B
    Vaccines (Basel); 2021 Dec; 9(12):. PubMed ID: 34960181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of COVID-19 vaccine subtypes, efficacy and geographical distributions.
    Francis AI; Ghany S; Gilkes T; Umakanthan S
    Postgrad Med J; 2022 May; 98(1159):389-394. PubMed ID: 37066438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Case of Acute Pulmonary Embolus after mRNA SARS-CoV-2 Immunization.
    Wiest NE; Johns GS; Edwards E
    Vaccines (Basel); 2021 Aug; 9(8):. PubMed ID: 34452028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study.
    Esquivel-Valerio JA; Skinner-Taylor CM; Moreno-Arquieta IA; Cardenas-de la Garza JA; Garcia-Arellano G; Gonzalez-Garcia PL; Almaraz-Juarez FDR; Galarza-Delgado DA
    Rheumatol Int; 2021 Dec; 41(12):2105-2108. PubMed ID: 34622311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-Coronavirus Vaccines: Past Investigations on SARS-CoV-1 and MERS-CoV, the Approved Vaccines from BioNTech/Pfizer, Moderna, Oxford/AstraZeneca and others under Development Against SARSCoV- 2 Infection.
    Costanzo M; De Giglio MAR; Roviello GN
    Curr Med Chem; 2022; 29(1):4-18. PubMed ID: 34355678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines.
    Rogliani P; Chetta A; Cazzola M; Calzetta L
    Vaccines (Basel); 2021 Mar; 9(3):. PubMed ID: 33807818
    [No Abstract]   [Full Text] [Related]  

  • 9. Review of COVID-19 Vaccines Approved in the United States of America for Emergency Use.
    Vasireddy D; Atluri P; Malayala SV; Vanaparthy R; Mohan G
    J Clin Med Res; 2021 Apr; 13(4):204-213. PubMed ID: 34007358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines.
    Doroftei B; Ciobica A; Ilie OD; Maftei R; Ilea C
    Diagnostics (Basel); 2021 Mar; 11(4):. PubMed ID: 33804914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of COVID-19 vaccines and their challenges (Review).
    Marfe G; Perna S; Shukla AK
    Exp Ther Med; 2021 Dec; 22(6):1407. PubMed ID: 34676000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 Vaccine Effectiveness: A Review of the First 6 Months of COVID-19 Vaccine Availability (1 January-30 June 2021).
    Hatcher SM; Endres-Dighe SM; Angulo FJ; Srivastava A; Nguyen JL; Khan F; Martin C; Swerdlow DL; McLaughlin JM; Ubaka-Blackmore N; Brown LM
    Vaccines (Basel); 2022 Mar; 10(3):. PubMed ID: 35335025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of The BNT162b2 COVID-19 mRNA and ChAdOx1 nCoV-19 Vaccines in Patients with Hemoglobinopathies.
    Radhwi OO; Jan H; Waheeb A; Alamri SS; Alahwal HM; Denetiu I; Almanzlawey A; Al-Marzouki AF; Almohammadi AT; Bahashwan SM; Barefah AS; Qari MH; Abuzenadah AM; Hashem AM
    Vaccines (Basel); 2022 Jan; 10(2):. PubMed ID: 35214610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developmental Status of the Potential Vaccines for the Mitigation of the COVID-19 Pandemic and a Focus on the Effectiveness of the Pfizer-BioNTech and Moderna mRNA Vaccines.
    Noor R
    Curr Clin Microbiol Rep; 2021; 8(3):178-185. PubMed ID: 33686365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials.
    Turley CB; Tables L; Fuller T; Sanders LJ; Scott H; Moodley A; Woodward Davis A; Leav B; Miller J; Schoemaker K; Vandebosch A; Sadoff J; Woo W; Cho I; Dunkle LM; Li S; van der Laan L; Gilbert PB; Follmann D; Jaynes H; Kublin JG; Baden LR; Goepfert P; Kotloff K; Gay CL; Falsey AR; El Sahly HM; Sobieszczyk ME; Huang Y; Neuzil KM; Corey L; Grinsztejn B; Gray G; Rouphael N; Luedtke A;
    Vaccine; 2023 Jul; 41(33):4899-4906. PubMed ID: 37385888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 Vaccines: Current Status and Implication for Use in Indonesia.
    Ophinni Y; Hasibuan AS; Widhani A; Maria S; Koesnoe S; Yunihastuti E; Karjadi TH; Rengganis I; Djauzi S
    Acta Med Indones; 2020 Oct; 52(4):388-412. PubMed ID: 33377885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Response in Regard to Hypersensitivity Reactions after COVID-19 Vaccination.
    Hsieh MH; Yamaguchi Y
    Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35884946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained COVID-19 vaccine willingness after safety concerns over the Oxford-AstraZeneca vaccine.
    Sønderskov KM; Dinesen PT; Østergaard SD
    Dan Med J; 2021 Mar; 68(5):. PubMed ID: 33870886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) in patients with multiple sclerosis: a statement by a working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society.
    Nojszewska M; Kalinowska A; Adamczyk-Sowa M; Kułakowska A; Bartosik-Psujek H
    Neurol Neurochir Pol; 2021; 55(1):8-11. PubMed ID: 33555604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets.
    Marsh GA; McAuley AJ; Au GG; Riddell S; Layton D; Singanallur NB; Layton R; Payne J; Durr PA; Bender H; Barr JA; Bingham J; Boyd V; Brown S; Bruce MP; Burkett K; Eastwood T; Edwards S; Gough T; Halpin K; Harper J; Holmes C; Horman WSJ; van Vuren PJ; Lowther S; Maynard K; McAuley KD; Neave MJ; Poole T; Rootes C; Rowe B; Soldani E; Stevens V; Stewart CR; Suen WW; Tachedjian M; Todd S; Trinidad L; Walter D; Watson N; Drew TW; Gilbert SC; Lambe T; Vasan SS
    NPJ Vaccines; 2021 May; 6(1):67. PubMed ID: 33972565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.